Pfister D, Heidenreich A, Porres D
Klinik für Urologie, Universitätsklinikum Aachen, Pauwelsstraße 30, 52074, Aachen, Deutschland,
Urologe A. 2013 Sep;52(9):1261-4. doi: 10.1007/s00120-013-3318-y.
In the prostate-specific antigen (PSA) era, prostate cancer is detected at more local stages. Nevertheless, depending on e.g. the differentiation stage there is recurrent disease in 10-40% of the cases with the need of further treatment. Once hormonal therapy has been initiated the disease can progress to the castration resistant stage and the question of chemotherapy arises. At this stage PSA sensitivity decreases. Although there is a significant improvement in survival only about 50% of the patients benefit from chemotherapy. Recently several new drugs have or will soon be approved in the setting of castration-resistant prostate cancer (CRPCA). Several prognostic molecular markers have been investigated. In this review some objective important biomarkers, proteins and targets will be presented.
在前列腺特异性抗原（PSA）时代，前列腺癌多在局部阶段被检测出来。然而，根据例如分化阶段等因素，10%-40%的病例会出现疾病复发，需要进一步治疗。一旦开始激素治疗，疾病可能进展至去势抵抗阶段，此时化疗问题就会出现。在此阶段，PSA敏感性降低。尽管生存率有显著提高，但只有约50%的患者能从化疗中获益。最近，几种新药已获批或即将在去势抵抗性前列腺癌（CRPCA）的治疗中获批。人们已经研究了多种预后分子标志物。在本综述中，将介绍一些客观重要的生物标志物、蛋白质和靶点。
